| 13 February 2018

Foundation Fighting Blindness and ProQR enter into partnership for Usher's Type 2A

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A 12

Foundation Fighting Blindness and ProQR have entered into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program into the clinic. QR-421a received orphan drug designation from the FDA.

| 04 January 2018

Spark Therapeutics INC announce models of patient access to LUXTURNA

On Wednesday January 3rd 2018,  Spark Therapeutics INC announced a series of payment models designed to help the process of patient access to its new gene therapy LUXTURNA in the United States, which is the only country where the once in a lifetime therapy is currently approved.  The company also announced the cost of the treatment.

| 11 October 2017

Study shows -Avoidable Blindness -Set to Increase in Future

On World Sight Day, eye care organisations around the world take note of new data that shows that global eye care efforts are at serious risk of being overwhelmed—unless we act now.

New data published in the Lancet Global Health shows that decades of declining “avoidable blindness”—those with uncorrected refractive errors and cataract—is plateauing, and is projected to increase between 2015 and 2050.

| 24 September 2017

AMD Week 2017

AMD (Age-related Macular Degeneration) is a condition that affects central vision and is associated with aging. It is important to note however that deteriorating vision is not an inevitable part of the aging process but the result of a particular condition that can, when diagnosed early enough be successfully treated.

In the over 50s, AMD is the leading cause of sight loss.

| 25 July 2017

Members News: 4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

4D Molecular Therapeutics (4DMT), a leader in adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s largest non-governmental source of research funding for inherited retinal degenerations (IRD) and dry age-related macular degeneration (AMD), today announced a partnership to develop intravitreal gene therapeutics for patients with these blinding conditions using 4DMT-proprietary AAV vectors.

| 09 June 2017

Counting down to New Zealand 2018!


Retina International is counting down to its World Congress 2018 which is now just eight months away! The RIWC takes place on the 10th and 11th of February 2018 in Auckland New Zealand.

This event will bring together some of the world’s foremost retinal scientists and clinicians along with the global leaders in patient advocacy and peer support. With a two day scientific programme covering the key developments in basic and clinical research as well as further information on therapeutic development it is an event not to be missed.

| 07 June 2017

Gordon and Lulie Gund Featured in New York Times Article

The Board of Directors and National Trustees of the Foundation Fighting Blindness (FFB ) are sharing  a recent New York Times article featuring Gordon and Lulie Gund.  The column, written by David Brooks, is focused on the power of philanthropy and the motivation of philanthropists.  Being mentioned is a welcome and fitting tribute to the Gunds’ commitment to finding treatments and cures for inherited retinal disease (IRDs) through supporting research for more than four decades and it is also an  opportunity to make more people aware of the work of FFB and its mission.

| 03 June 2017

Macula and Retina Patient Meeting – Seville, October 20 & 21, 2017


Retina France and Macula Retina Spain are pleased to announce the first Patient Congress on The Retina and Macula, which will take place in Seville, Spain on Friday 20th and Saturday 21st of October, 2017. This initiative was conceived In October 2016 by the team of Jacinto Zulueta of Macula Retina Spain and Retina France at an event organised by Retina International.

Join Our Mailing List